Emirates Health Services (EHS) has signed a memorandum of understanding with Novo Nordisk Pharma Gulf to collaborate on areas of common interest for the two entities, most notably in terms of innovation in healthcare, in a bid to enhance health services and implement the most advanced medical breakthroughs.
The MoU reflects EHS’ commitment to expanding its network of strategic partnerships and create a platform for exchanging expertise in healthcare and advanced medical treatments. This, in turn, paves the way for providing innovative health services that meet the needs of all customers.
The agreement was signed by His Excellency Dr Yousif Mohammed Al Serkal, Director-General of EHS, and Mr Mads Bo Larsen, Vice President and General Manager of Novo Nordisk Pharma Gulf.
H.E. Dr Al Serkal asserted that: “Signing this memorandum of understanding with Novo Nordisk Pharma Gulf is in line with our objectives at Emirates Health Services to provide innovative and sustainable health services, enhance the efficiency of the health system as a whole, and position the sector as a leader in providing world-class healthcare that is up to the highest standards and meets every requirement of patients and customers.”
“Strengthening partnerships, setting effective cooperation frameworks, and forming new partnerships is a core part of our goals and ambitions at EHS to establish a comprehensive network of local, regional, and global partners to collaborate with towards promoting sustainability and offering the UAE community with outstanding and continuously evolving health services that meet the highest international standards,” H.E. Al Serkal added.
For his part, Dr. Abdullah Al-Naqbi, Acting Executive Director of the Supportive Health Services Sector at EHS, said: “Our approach at Emirates Health Services aims to provide health services that employ the latest and most advanced technologies and artificial intelligence applications, in addition to creating new opportunities for collaboration with major companies and leading health authorities in the region and around the world. We strive to facilitate the exchange of expertise, acquiring new skills, enhancing efficiency and quality of performance, and empowering workers across the healthcare sector.”
Under the terms of the MoU, Novo Nordisk Pharma Gulf pledges to provide 12 months of free treatment with its oral Semaglutide drug for 50 patients with type 2 diabetes. Therapeutic outcomes are set to be evaluated by EHS within six months. The company will also provide support through scientific communication treating physicians on the management of type 2 diabetes.
Furthermore, the agreement aims to ensure coordination between the two entities through consistent communication between healthcare providers at EHS, on one hand, and medical directors and specialists at Novo Nordisk Pharma Gulf, on the other, to provide guidance on diabetes treatment. To that end, the company will provide EHS with up-to-date global and local algorithms for diabetes treatment.
The two entities will also collaborate on educational programmes and panel discussions for healthcare providers at hospitals and healthcare centres under the EHS umbrella that offer diabetes treatments.
Commenting on the MoU, Mads Bo Larsen said: “At Novo Nordisk Pharma Gulf, we constantly strive to be part of initiatives that offer care for diabetes patients in the UAE. With that in mind, we are proud of the integrated and effective coordination we have established with Emirates Health Services on these initiatives, which form part of EHS’ efforts to develop and implement innovative healthcare solutions that meet the requirements and standards of the future.”
Meanwhile, Mike Maziar, Executive Vice President of International Operations at Novo Nordisk, asserted that the company hopes the MoU will contribute to providing the latest and most innovative treatments for type 2 diabetes, strengthening Emirates Health Services’ position as a leader in providing innovative treatments. “We look forward to a strategic partnership with Emirates Health Services in the present and well into the future,” he added.
For her part, Aseel Nassar, Public Affairs, External Communications Manager and Sustainability Lead at Novo Nordisk Pharma Gulf, said: “This agreement aims to strengthen our well-established relations with health authorities in the UAE, offering support and developing capacities across the entirety of the medical system. We are proud of this constructive collaboration we have established with Emirates Health Services to support the healthcare community and society as a whole. It forms part of our commitment to shore up the sustainable development process and make a positive impact on quality of life for diabetes patients in the UAE.”
Over the past few months, Emirates Health Services has concluded a series of MoUs and agreements with leading institutions, companies, and medical establishments around the world, in an effort to promote sustainability and drive the development of high-quality of healthcare services, available to patients and customers across the UAE.